Tuberous Sclerosis Complex (TSC): A Patient Guide

Tuberous Sclerosis Complex (TSC) is a lifelong genetic condition that causes various lesions, malformations, and non-cancerous growths, called hamartomas, to develop in various parts of the body ^[1]. While many of these are hamartomas, the condition also causes developmental malformations in the brain (cortical tubers), cystic lung disease, and rarely, malignant renal tumors. These features most commonly appear in the brain, kidneys, heart, lungs, skin, and eyes. They can impact how different organs function as they grow or press on healthy tissue. The condition is highly variable, meaning that no two people will experience it in exactly the same way, even within the same family ^[2].

At the biological level, TSC is caused by a change in one of two genes, TSC1 or TSC2, which normally act like “brakes” on cell growth ^[3]. When these genes are mutated, they can no longer restrain a growth-regulating system in the cell called the mTOR pathway ^[4]. This causes cells to grow and divide more than they should. Understanding this pathway has been a major breakthrough, as it led to the development of targeted therapies called mTOR inhibitors that can inhibit this downstream pathway and help manage selected manifestations across multiple organ systems ^[5].

Living with TSC requires a proactive approach centered on regular surveillance and early intervention. Because the brain is often involved, many children develop epilepsy—including a specific type called infantile spasms—which requires rapid diagnosis and treatment to protect long-term development ^[6]. Beyond physical health, the majority of people with TSC experience a range of learning, behavioral, or psychiatric challenges known as TAND (TSC-Associated Neuropsychiatric Disorders), which require annual screening and specialized support ^[7].

While a TSC diagnosis can be complex, management has been transformed by modern medicine. By working with a multidisciplinary team to monitor organ health and using targeted treatments when necessary, families can stay ahead of the condition. Please note: Surveillance and treatment decisions must be highly individualized. Do not start, stop, or change antiseizure or mTOR medications based on this guide alone; always discuss your specific care plan with your medical team ^[8].